[How I treat....psoriasis comorbidities by adalimumab (Humira) anti-TNFalpha].
Psoriasis is primarily a chronic inflammatory skin disease burdened by some comorbidities including psoriatic alopecia, arthropathies, Crohn's disease, the metabolic syndrome and some cardiovascular involvement. During the past years, several biologicals corresponding to monoclonal antibodies were offered to treat psoriasis refractory to other potent conventional treatments. We review the effects of biologicals, in particular adalimumab (Humira), on psoriatic comorbidities.
Service de Dermatopathologie, CHU de Liège. gerald.pierard@ulg.ac.be
C
C
Piérard-Franchimont
F
F
Henry
G
G
Szepetiuk
G E
GE
Piérard
D000068879:Adalimumab; D000505:Alopecia / Q000150:complications / Q000188:drug therapy; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000209:etiology; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy; D006801:Humans; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab